They are a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients.
This company devoted to the development of oncology products that can improve the lives and outcomes of cancer patients.
Their product pipeline reflects this complexity and includes small molecules designed to attack cancer cells directly and synthetic vaccines designed to stimulate an immune response against cancer cells (cancer immunotherapy). Each of their product candidates aims a specific cancer-associated molecule and is designed to attack cancer cells while limiting damage to healthy tissue.
Moreover, Oncothyreon's discovery platform named Protocell Platform is an innovative approach to the development of multiple therapeutic candidates using aimed nanoparticles called protocells. In addition, they
are developing immunotherapies and small molecules that target multiple cancer indications.
2601 Fourth Avenue, Suite 500